Evidence map›Paper›PMID 34842490›Full record

ArticleScience progress2021

Chemotherapy in combination with pembrolizumab and antiangiogenesis in young patients with advanced primary pulmonary mucinous adenocarcinoma: Two case reports.

Daibing Zhou, Wumaier Gulinuer, Ning Zhu

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Science progress, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Daibing ZhouDepartments of Respiratory and Critical Care Medicine, 159397Huashan Hospital, Fudan University, Shanghai, PR China.ORCID 0000-0001-7723-1470
Wumaier GulinuerDepartments of Respiratory and Critical Care Medicine, 159397Huashan Hospital, Fudan University, Shanghai, PR China.
Ning ZhuDepartments of Respiratory and Critical Care Medicine, 159397Huashan Hospital, Fudan University, Shanghai, PR China.
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary pulmonary mucinous adenocarcinoma is an unusual histological type of non-small cell lung cancer and has a rare prevalence at a young age. There is no standard first-line therapy for advanced primary pulmonary mucinous adenocarcinoma in children and young adults-this study reports two rare cases of primary pulmonary mucinous adenocarcinoma with

Indexed as

AdenocarcinomaAdenocarcinoma, MucinousAdenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsAdolescentAdultAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedChildHumansImmunotherapyMaleYoung AdultAngiogenesis InhibitorsAntibodies, Monoclonal, Humanizedpembrolizumabangiogenesis inhibitorschemotherapyimmunotherapyNon-small cell lung cancerprimary pulmonary mucinous adenocarcinoma

Identifiers

PMID34842490
PMCPMC10461373
OpenAlexW3215893661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.